Scale-Up of Academic Mesenchymal Stromal Cell Production

Many clinical trials have reported the use of mesenchymal stromal cells (MSCs) following the indication of severe SARS-CoV-2 infection. However, in the COVID19 pandemic context, academic laboratories had to adapt a production process to obtain MSCs in a very short time. Production processes, especia...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2023-06, Vol.12 (13), p.4414
Main Authors: Laroye, Caroline, Gauthier, Mélanie, Morello, Jessica, Charif, Naceur, Cannard, Véronique Latger, Bonnet, Céline, Lozniewski, Alain, Tchirkov, Andrei, De Isla, Natalia, Decot, Véronique, Reppel, Loïc, Bensoussan, Danièle
Format: Article
Language:English
Subjects:
Bone marrow
Cell culture
Cell research
Cellular therapy
Clinical medicine
Clinical trials
Connective tissue cells
COVID-19
Cryopreservation
Cryopreservation of organs, tissues, etc
Environmental monitoring
Health aspects
Laboratories
Life Sciences
Methods
Physiological aspects
Raw materials
Regulatory agencies
Sepsis
Severe acute respiratory syndrome coronavirus 2
Umbilical cord
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many clinical trials have reported the use of mesenchymal stromal cells (MSCs) following the indication of severe SARS-CoV-2 infection. However, in the COVID19 pandemic context, academic laboratories had to adapt a production process to obtain MSCs in a very short time. Production processes, especially freezing/thawing cycles, or culture medium have impacts on MSC properties. We evaluated the impact of an intermediate cryopreservation state during MSC culture to increase production yields. Seven Wharton's jelly (WJ)-MSC batches generated from seven different umbilical cords with only one cryopreservation step and 13 WJ-MSC batches produced with intermediate freezing were formed according to good manufacturing practices. The identity (phenotype and clonogenic capacities), safety (karyotype, telomerase activity, sterility, and donor qualification), and functionality (viability, mixed lymphocyte reaction) were analyzed. No significant differences between MSC production processes were observed, except for the clonogenic capacity, which was decreased, although it always remained above our specifications. Intermediate cryopreservation allows an increase in the production yield and has little impact on the basic characteristics of MSCs.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12134414